Skip to main content
Oxford Research Peptides
MECHANISM NOTE

Retatrutide Mechanism of Action

How a single peptide engages three related class B G-protein-coupled receptors — GLP-1R, GIPR and GCGR — and what the published literature reports about the downstream signalling.

QUICK ANSWER
TL;DR

Quick answer

Retatrutide is reported as a balanced full agonist of the GLP-1, GIP and glucagon receptors. All three are class B G-protein-coupled receptors coupled to Gαs, so activation converges on elevation of intracellular cAMP.
EXTENDED ANSWER
AI-ready

Extended answer

How does Retatrutide act at GLP-1R, GIPR and GCGR?

Retatrutide binds and activates three related class B secretin-like G-protein-coupled receptors — GLP-1R, GIPR and GCGR — from a single peptide backbone. All three receptors couple primarily to Gαs, elevate intracellular cyclic AMP and engage downstream effectors including protein kinase A and Epac. The reported discovery pharmacology describes balanced full-agonist activity across the three targets in cell-based cAMP assays, meaning each receptor is driven to near-maximal efficacy at comparable relative potency. The biological outputs differ by tissue: GLP-1R and GIPR support incretin-mediated insulin secretion and satiety signalling, while GCGR contributes to hepatic glucose output and energy expenditure. Long-term receptor adaptations and the relative contribution of each receptor to observed clinical effects remain open questions in the published literature.
KEY FACTS

Key facts

Receptor class
Class B GPCR (× 3)
Coupling
Gαs / cAMP
Endogenous ligands
GLP-1, GIP, glucagon
Reported activity
Balanced full agonism

The three receptors

GLP-1R, GIPR and GCGR are members of the class B (secretin-like) G-protein-coupled receptor family. Each receptor's endogenous ligand is a short peptide hormone released in response to nutrient or metabolic cues.[4][6]

  • GLP-1R — receptor for glucagon-like peptide-1; associated with insulin secretion, satiety and gastric-emptying signalling.[5]
  • GIPR — receptor for glucose-dependent insulinotropic polypeptide; part of the incretin axis.[4]
  • GCGR — glucagon receptor; involved in hepatic glucose output and energy expenditure signalling.

Reported pharmacology

In the original discovery-pharmacology publication, Retatrutide is described as a balanced agonist at all three receptors in cell-based cAMP assays — that is, it activates each receptor to near-maximal efficacy at comparable relative potencies.[1]

Because all three receptors couple to Gαs and elevate cAMP, the overall signalling output described in the literature is convergent at the cAMP level, even though the tissue distribution and physiological consequences of each receptor differ.[6]

Structural strategy

Retatrutide's sequence is engineered to preserve engagement at three related but distinct receptor pockets, and it carries a fatty-acid modification that supports albumin binding and an extended plasma half-life — a strategy shared with other long-acting incretin analogues.[1]

Assay considerations

Comparative pharmacology reports for Retatrutide typically use orthogonal cAMP-response readouts at each receptor. When designing in-vitro receptor-binding or functional assays, matching the receptor construct, cell line and readout used in the primary literature enables direct comparison of results.

What the literature does not yet resolve

  • The precise contribution of each of the three receptors to observed clinical effects.
  • Long-term signalling adaptations (e.g. receptor desensitisation) beyond published trial durations.
  • Cross-lab reproducibility of relative potency values across different assay platforms.

References6

  1. 1.

    Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metabolism. 2022;34(9):1234-1247.

    DOI: 10.1016/j.cmet.2022.07.013PMID: 35985340
  2. 2.

    Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.. New England Journal of Medicine. 2023;389(6):514-526.

    DOI: 10.1056/NEJMoa2301972PMID: 37366315
  3. 3.

    Rosenstock J, Frias J, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.. The Lancet. 2023;402(10401):529-544.

    DOI: 10.1016/S0140-6736(23)01053-XPMID: 37385275
  4. 4.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.. Gastroenterology. 2007;132(6):2131-2157.

    DOI: 10.1053/j.gastro.2007.03.054PMID: 17498508
  5. 5.

    Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1.. Cell Metabolism. 2018;27(4):740-756.

    DOI: 10.1016/j.cmet.2018.03.001PMID: 29617641
  6. 6.

    de Graaf C, Donnelly D, Wootten D, et al.. Glucagon-like peptide-1 and its class B G protein–coupled receptors: a long march to therapeutic successes.. Pharmacological Reviews. 2016;68(4):954-1013.

    DOI: 10.1124/pr.115.011395PMID: 27736833
EVIDENCE SUMMARY
Evidence

Evidence summary

Moderate evidence
Research confidenceModerate confidence
Mechanism is characterised in the sponsor-led discovery paper and supported by broader incretin-pharmacology literature; some downstream questions remain open.
RESEARCH LIMITATIONS

Research limitations

  • Primary pharmacology is described in a single discovery paper; independent replication continues to develop.
  • Relative receptor contribution in vivo has not been fully resolved.
  • Long-term signalling data beyond published trial durations are limited.
RELATED GUIDES
COMPOUND REFERENCE
EDITORIAL NOTICE

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
VERSION HISTORY
Editorial Team
Oxford Research Peptides Editorial Team
In-house editorial staff
Oxford Research Peptides
Scientific Reviewer
Scientific Review Panel
Independent scientific review
Oxford Research Peptides

Publication information

Published
2026-07-15
Updated
2026-07-15
Reviewed
2026-07-15
Version
1.0

Revision history

  1. v1.02026-07-15· Editorial Team

    Initial publication as part of the Retatrutide authority cluster (Release 4.0).

Editorial standards

Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.

Conflict of interest

Oxford Research Peptides supplies research-grade reference peptides commercially. Editorial pages are drafted and reviewed to describe published scientific literature accurately and do not recommend, promote or endorse any specific commercial product. Product mentions on educational pages are strictly for cross-referencing catalogue entries.

Next scheduled review: 2028-01-15. Our research methodology describes how the review is conducted.

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
Published: 2026-07-15Updated: 2026-07-15